Zometa zoledronic acid: Phase III data

In the Phase III Myeloma IX Study in 1,960 evaluable patients, Zometa significantly reduced the proportion of patients experiencing an SRE vs. Bonefos clodronate (27% vs. 35.3%, p=0.0004). Additionally, Zometa significantly improved OS (50 vs. 44.5 months, p=0.0118) and PFS compared to Bonefos (19.5 vs. 17.5 months, p=0.0179). Patients received 4 mg Zometa every 21-28 days or 1,600 mg daily Bonefos. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...